Rosetta Genomics        is an international leader in  diagnostic and therapeutic product development and medical research involving micro-ribonucleic acid, commonly known as microRNA.

Rosetta has developed an extensive integrated platform in microRNA research and data that brings together the most advanced findings and capabilities in genomics, bioinformatics and biotechnology.

As a result, the company is recognized by leaders in the pharmaceutical and biotechnology industries and in academia as an important resource  in the rapidly growing area of microRNA product development.  Originally believed to be components of nonfunctioning “junk DNA”, microRNAs are now known to play a critical role in essential cellular functions in the body, including protein production, cell differentiation and cell death.

Because these functions also affect disease progression, many recent research findings indicate that microRNA itself is a pivotal factor in numerous aspects of human health. By understanding and harnessing the power of microRNA, researchers see significant potential to develop new treatments and diagnostic products for many serious illnesses, including targets in cancer, infectious diseases and autoimmune disorders. Building on innovative avenues of medical research made possible by the Human Genome Project, Rosetta Genomics is introducing a new era in the history of healthcare diagnostics and drug discovery - the microRNA Era.

 A Solid Platform for Success       Rosetta Genomics was founded in 2000 by a small group of visionaries who were among the very first researchers to recognize the potential of microRNA. Today, Rosetta has one of the world’s most experienced medical research teams dedicated to microRNA product development.

Though we are working in a relatively new field, our outstanding team has already achieved significant results in early-stage development, innovative technologies and intellectual property in microRNA.  Programs conducted at Rosetta Genomics include many of the earliest and most important initiatives in microRNA research – and the history of major developments in this field is still being written here today.

The company has made significant progress in efforts to advance a pipeline of promising microRNA-based therapeutic and diagnostic tools, including targets in oncology, infectious disease and other areas.

In addition, Rosetta believes its expanding intellectual property portfolio makes the company an optimal partner and collaborator for others engaged in microRNA product development.  With international reach, and a a team of talented scientists with extensive experience in all areas of genomic research and development, Rosetta Genomics is at the forefront of the rapidly expanding global healthcare focus on microRNA. In the years ahead, Rosetta plans to pursue multiple programs in microRNA product development, reflecting potentially significant commercial opportunities and important new programs in disease prevention and treatment for millions of people around the world.

The Rosetta Stone  

Rosetta Genomics takes its name from the Rosetta Stone, a large ancient stone engraving discovered by Napoleon’s troops in 1799 in a small village on the Nile Delta.

The Rosetta Stone includes sections of carved text presented in three different ancient scripts, including ancient Egyptian Hieroglyphics.

For the first time, thanks to the Rosetta Stone, researchers were able to decipher ancient Egyptian Hieroglyphics, thereby opening the Ancient World to modern eyes.

As the Rosetta Stone helped to decode the meaning of ancient texts, so Rosetta Genomics is dedicated to unlocking the mysteries of microRNA. We believe our efforts will help many others to understand this new “language” in healthcare and introduce a new generation of diagnostic and therapeutic products to improve human health.